About US
Contact us
-
Stada stymied in bids for Russian M&AGermany's Stada wants to expand in Russia. But attempts to buy Russian drugmakers have so far failed--despite months of effort--leaving the company with a big debt burden and stagnant home market, Reu2012/3/16
-
J&J's Weldon due for $143M retirement packageA 40-year career at Johnson & Johnson ($JNJ) can really pay off, especially if you cap it with a 10-year stint as CEO. That's the company's explanation for the whopping $143 million retirement pac2012/3/16
-
J&J's Weldon due for $143M retirement packageA 40-year career at Johnson & Johnson ($JNJ) can really pay off, especially if you cap it with a 10-year stint as CEO. That's the company's explanation for the whopping $143 million retirement pac2012/3/16
-
Rosa PK/PD Collaboration with Pfizer to be Presented at ASCPT 2012SAN CARLOS,, CA, March 09, 2012 /24-7PressRelease/ -- Rosa & Co. LLC, a drug development advisory firm with expertise in PK/PD and drug-disease modeling and simulation, today announced that result2012/3/15
-
Chinese officials intent on 'Anhui model' for price cutsAs China's National People's Congress ends in Beijing, Chinese politicians are repeating their pledge to make healthcare more affordable. Unfortunately for drugmakers, that means officials are also pl2012/3/15
-
After big hike in 2011, GSK CEO's pay set to jump againGlaxoSmithKline ($GSK) CEO Andrew Witty (photo) saw a big pay hike in 2011--and he's due another increase this year, the company's compensation committee says.Last year, Witty collected a pay package2012/3/14
-
Japan may open door to more foreign-approved drugsHere's another hint of Japan's new openness to Big Pharma: a proposed compassionate use program. The government is considering allowing drugs for serious diseases to be sold in Japan while they're sti2012/3/14
-
FDA drafts rules for prior review of DTC television adsMoving toward mandatory review of direct-to-consumer advertising, the FDA has released draft rules for which sorts of materials need review--and in which form they can be submitted. The agency guidanc2012/3/13
-
Pfizer aims to jump start stalled arthritis-pain drugsPfizer ($PFE) is making a pitch for reviving the anti-nerve growth factor drug it shelved two years ago on safety concerns. The arthritis pain treatment is one of several anti-NGF drugs, so if FDA all2012/3/13
-
Biopharma workers balance good, bad and ugly in new surveyFirst, the good news about what biopharma employees are thinking today: Things aren't as bad as they used to be--for some. That's the bottom line of a new industry survey conducted by Challenger, Gray2012/3/12